Viveve Medical (VIVE) Receives Daily Media Sentiment Rating of 0.16

News headlines about Viveve Medical (NASDAQ:VIVE) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Viveve Medical earned a news impact score of 0.16 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 46.0810023174452 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the headlines that may have impacted Accern’s scoring:

VIVE has been the topic of several recent analyst reports. B. Riley reissued a “buy” rating and issued a $10.00 target price on shares of Viveve Medical in a research note on Wednesday, May 17th. Maxim Group reissued a “buy” rating and issued a $11.00 target price on shares of Viveve Medical in a research note on Friday. ValuEngine raised shares of Viveve Medical from a “sell” rating to a “hold” rating in a research note on Friday, June 9th. Raymond James Financial, Inc. began coverage on shares of Viveve Medical in a research note on Thursday, May 25th. They issued an “outperform” rating and a $10.00 price target on the stock. Finally, Cowen and Company began coverage on shares of Viveve Medical in a research note on Wednesday, May 3rd. They issued an “outperform” rating and a $11.00 price target on the stock. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $12.80.

Viveve Medical (VIVE) traded down 6.24% on Friday, reaching $6.61. 585,793 shares of the company traded hands. Viveve Medical has a 1-year low of $3.75 and a 1-year high of $11.16. The stock has a 50 day moving average of $7.02 and a 200-day moving average of $6.45. The stock’s market capitalization is $128.06 million.

Viveve Medical (NASDAQ:VIVE) last issued its quarterly earnings results on Thursday, August 10th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.33) by $0.21. The business had revenue of $3.08 million for the quarter, compared to analysts’ expectations of $3.24 million. Viveve Medical had a negative return on equity of 283.57% and a negative net margin of 266.93%. The firm’s revenue for the quarter was up 97.4% on a year-over-year basis. During the same quarter last year, the company earned ($0.66) earnings per share. On average, equities analysts anticipate that Viveve Medical will post ($1.81) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Viveve Medical (VIVE) Receives Daily Media Sentiment Rating of 0.16” was first posted by Rincon Hill News and is the property of of Rincon Hill News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://rinconhillneighbors.org/2017/08/13/viveve-medical-vive-given-daily-news-sentiment-score-of-0-16-updated.html.

About Viveve Medical

Viveve Medical, Inc designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company’s, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories.

Receive News & Ratings for Viveve Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical Inc. and related companies with our FREE daily email newsletter.

 

Latest News



Leave a Reply

 
© 2006-2017 Rincon Hill News.